期刊文献+

紫杉醇对人胰腺癌细胞株BxPC-3增殖抑制作用的研究

Study of anti-proliferation of paclitaxel on human pancreatic cancer cell line BxPC-3 in vitro
暂未订购
导出
摘要 目的:通过体外实验探讨紫杉醇(paclitaxel,TAX)对人胰腺癌细胞株Bx-PC-3的增殖抑制作用。方法:人胰腺癌细胞株BxPC-3经过不同浓度的TAX作用不同时间后,在倒置显微镜下观察细胞形态学改变;用甲基噻唑基四唑试验(MTT)检测细胞抑制率;用流式细胞仪分析细胞周期变化。结果:TAX对人胰腺癌细胞株BxPC-3有明显的生长抑制作用,且呈剂量、时间依赖关系。流式细胞仪分析结果显示,BxPC-3细胞经过1000nmol/LTAX分别作用24和48h后,G2~M期细胞比例分别为(66.39±0.23)%和(48.49±1.47)%,明显高于对照组(8.67±2.32)%和(10.85±2.43)%,t值分别为49.41和26.49,P值均为0.000,提示存在G2~M期阻滞。结论:TAX可使人胰腺癌细胞株BxPC-3的生长受到抑制,BxPC-3细胞经过TAX作用后被阻滞于G2~M期。 OBJECTIVE : To assess the anti-proliferative effect of paclitaxel on human pancreatic cancer cell line BxPC-3 in vitro. METHODS: The human pancrecatic cancer cell line BxPC-3 was treated with paclitaxel of different concentrations for different time. The changes of cell morphology were observed under an inverted light microscope. The inhibition rates of cells were detected through MTT assay. The changes of cell cycle were analysed through flow cytometry. RESULTS.. The growth inhibhion effect of paclitaxel was observed on human pancreatic cancer cell line Bx- PC-3, and the growth inhibition effect was time and dosage dependent. The result of flow cytometry showed that cells in G2 -M phase were increased after exposure to 1 000 nmol/L paclitaxel for 24 h and 48 h, the proportions of cells in G2 - M phase were (66.39±0.23)% and (48. 49± 1.47)%, and those in control group were (8.67±2.32)% and (10.85±2.43)%, t was 49.41 and 26.49, P was 0. 000 and 0. 000, indicating that the cells were blocked in G2-M phase. CONCLUSION.. Growth inhibhion effect is of paclitaxel observed on human pancreatic cancer cell line BxPC-3, and the cells exposed to paclhaxel are blocked in G2-M phase.
出处 《中华肿瘤防治杂志》 CAS 2007年第22期1694-1697,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 胰腺肿瘤/病理学 增殖抑制 流式细胞术 抗肿瘤药 pancreatic neoplasms/pathology proliferative inhibition flow cytometry antineoplastic agents
  • 相关文献

参考文献14

二级参考文献37

  • 1林李嵩,林国础,陈万涛,郭伟,姚明.紫杉醇对腺样囊性癌抗瘤作用及对细胞周期的影响[J].中华口腔医学杂志,2001,36(6). 被引量:9
  • 2[1]Ajani JA.Treatment of patients with upper gastrointestinal carcinomas[J]. Semin Oncol, 1997,24(6 Suppl 19):1972-1987.
  • 3[2]Ilson DH, Ajani J, Bhalla K, et al. Phase Ⅱ trial of paclitaxel, fluorouracil and cisplatin in patients with advanced carcinoma of the esophagus[J]. J Clin Oncol,1998,16(5):1826-1834.
  • 4[3]Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced,recurrent or metastatic esophageal cancer[J]. Br J Cancer,1998,78(4):511-517.
  • 5[4]Kelsen D, Ginsberg R, Bains M, et al. A phase Ⅱ trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report[J]. Semin Oncol,1997,24(6 Suppl 19):1977-1989.
  • 6[5]Safran H, Akerman P, Cioffi W, et al. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas,stomach and gastroesophageal junction[J]. Semin Radiat Oncol,1999,9(2 Suppl 1):53-64.
  • 7[6]Meluch AA, Hainsworth JD, Gray JR, et al. Preoperative combined modality therapy with paclitaxel, carboplatin,prolonged infusion 5_fluorouracil, and radiation therapy in localized esophageal cancer:preliminary results of a Minnie Pearl Cancer Research Network phase Ⅱ trial[J]. Cancer J Sci Am,1999,5(2):84-93.
  • 8[7]Ajani JA, Fairweather J, Dumas P, et al. Phase Ⅱ study of Taxol in patients with advanced gastric carcinoma[J]. Cancer J Sci Am,1998,4(4):269-276.
  • 9[8]Cascinu S, Graziano F, Cardarelli N, et al. Phase Ⅱ study of paclitaxel in pretreated advanced gastric cancer[J]. Anticancer Drugs,1998,9(4):307-312.
  • 10[9]urad AM, Petroianu A, Guimaraes RC, et al. Phase Ⅱ trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen[J]. Am J Clin Oncol,1999, 22(6):580-591.

共引文献155

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部